Farnesyl transferase inhibitors in clinical development

Expert Opinion on Investigational Drugs

Volumn 12, Issue 6, 2003, Pages 943-954

  Caponigro, Francesco ^a   Casale, Marina ^a   Bryce, Jane ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Anticancer therapy; Farnesyl transferase inhibitors; ras oncogene

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ANTICONVULSIVE AGENT; BINDING PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; DAUNORUBICIN; DOCETAXEL; ENZYME INDUCING AGENT; FLUOROURACIL; GEMCITABINE; IMATINIB; IRINOTECAN; ISIS 2503; L 778123; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; RHO FACTOR; SORAFENIB; TAMOXIFEN; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; CYTOTOXICITY; DEHYDRATION; DISEASE SEVERITY; DOWNSTREAM PROCESSING; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEVER; FOOT DISEASE; GASTROINTESTINAL SYMPTOM; HAND DISEASE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IN VIVO STUDY; KIDNEY FAILURE; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CLINICAL TRIALS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 0038685910     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.6.943     Document Type: Review

References (66)

1. BOS JL: Ras oncogenes in human cancer. A review. Cancer Res. (1989) 49:4682-4689.
2. BEAUPRE DM, KURZROCK R: RAS and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. (1999) 17:1071-1079.
3. FIELD JK, SPANDIDOS DA. The role of ras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis (review). Anticancer Res. (1990) 10:1-22.
4. ROWINSKY EK, WINDLE JJ, VON HOFF D: Ras Protein Farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol. (1999) 17:3631-3652.
5. ADJEI AA. Blocking oncogenic ras signaling for cancer therapy. J. Natl. Cancer Inst. (2001) 93:1062-1074.
6. STOKOE D, MACDONALD SG, CADWALLADER K et al.: Activation of Raf as a result of recruitment to the plasma membrane. Science (1994) 264:1463-1467.
7. LEEVERS SJ, PATERSON HF, MARSHALL CJ: Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (1994) 369:411-414.
8. YAN J, ROY S, APOLLONI A et al.: Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J. Biol. Chem. (1998) 273:24052-24056.
9. PRENDERGAST GC: Mode of action of farnesyltransferase inhibitors. Lancet Oncol. (2000) 1:73.
10. ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I trial of the farnesyl transferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res. (2000) 60:1871-1877.
11. ESKENS FALM AWADA A, CUTLER DL et al.: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. (2001) 19:1167-1175.
12. AWADA A, ESKENS FALM, PICCART M et al.: Phase I and pharmacological study of the oral farnesiltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumors. Eur. J. Cancer (2002) 38:2272-2278.
13. KIES MS, CLAYMAN GL, EL-NAGGAR AK et al.: Induction therapy with SCH66336, a farnesyl transferase inhibitor, in squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol. (2001) 20:225a (Abstract 896).
14. LERSCH C, VAN CUTSEM E, AMADO R et al.: Randomized Phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc. Am. Soc. Clin. Oncol. (2001) 20:153a (Abstract 608).
15. VINQUIST E, MOORE MJ, CHI K et al.: NCIC CTG IND.28. A Phase II study of farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol. (2001):197a (Abstract 785).
16. SHI B, YAREMKO B, HAJIAM G et al.: The farnesyl protein transferase inhibitor SCH 66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother. Pharmacol. (2000) 46:387-393.
17. ADJEI AA, DAVIS JN, BRUZEK LM et al.: Synergy of the protein transferase inhibitor SCH 66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. (2001) 7:1438-1445.
18. NAKAJIMA A. TAUCHIT, SUMI M et al.: Efficacy of SCH 66336, the farnesyl transferase inhibitor, against Gleevec-resistant BCR-ABL-positive cells. Proc. Am. Assoc. Cancer Res. (2002) 43:855 (Abstract 4235).
19. WANG E, CASCIANO CN, CLEMENT RP, JOHNSON WW: The farnesyl protein transferase inhibitor SCH 66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res. (2001) 61:7525-7529.
20. HURWITZ HI, AMADO R, PRAGER D et al.: Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH 66336 plus gemcitabine in advanced cancer. Proc. Am. Soc. Clin. Oncol. (2000) 19:185a (Abstract 717).
21. KIM ES, GLISSON BS, MEYERS ML et al.: A Phase I/II study of the farnesyl transferase inhibitor (FTI) SCH 66336 with paclitaxel in patients with solid rumors. Proc. Am. Assoc. Cancer Res. (2001) 42:488 (Abstract 2629).
22. KIM ES, KIES MS, FOSSELLA FV et al.: A Phase I/II study of the farnesyl transferase inhibitor (FTI) SCH 66336 (lonafarnib) with paclitaxel in taxane refractory/resistant patients with non-small cell lung cancer (NSCLC): final report. Proc. Am. Assoc. Cancer Res. (2002) 43:550 (Abstract 2735).
23. PIERSON AS, HOLDEN SN, BASCHE M et al.: A Phase I, pharmacokinetic and biological study of the farnesyl transferase inhibitor Sarasar (lonafarnib, SCH 66336), cisplatin, and gemcitabine in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:92a (Abstract 365).
24. SPRAGUE E, VOKES EE, GARLAND LL et al.: Phase I study of continuous lonafarnib plus paclitaxel and carboplatin in refractory or advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:28b (Abstract 1920).
25. ZUJEWSKI J, HORAK ID, BOL CJ et al.: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2000) 18:927-941.
26. CRUL M, DE KLERK GJ, SWART M et al.: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. (2002) 20:2726-2735.
27. JOHNSTON SRD, HICKISH T, ELLIS PA et al.: Efficacy and tolerability of two dosing regimens of R115777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:35a (Abstract 138).
28. ADJEI AA, MAUER A, MARKS R et al.: A Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:290a (Abstract 1156).
29. HEYMACH JV, DE PORRE PM, DEVORE RF et al.: Phase II study of the farnesyl transferase inhibitor R115777 (Zarnestra) in patients with relapsed small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:319a (Abstract 1275).
30. COHEN SJ, HO L, RANGANATHAN S et al.: Phase II and pharmacodynamic trial of the farnesiltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2002) 21:137a (Abstract 545).
31. MACDONALD JS, CHANSKY K, WHITEHEAD R et al.: A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group (SWOG) study. Proc. Am. Soc. Clin. Oncol. (2002) 21:138a (Abstract 548).
32. CLOUGHESY TF, KUHN J, WEN P et al.: Phase II trial of R115777 (Zarnestra) in patients with recurrent glioma not taking enzyme inducing anti epilectic drugs (EIAED): a North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002) 21:80a (Abstract 317).
33. KUHN JG, PRADOS M, ROBINS HI et al.: Phase I trial of R115777 (Zarnestra) in patients with recurrent malignant glioma taking enzyme inducing anti epiletic drugs (EIAED). A North American Brain Tumor Consortium (NABTC) report. Proc. Am. Soc. Clin. Oncol. (2002) 21:86a (Abstract 342).
34. HAROUSSEAU JL, STONE R, THOMAS X et al.: Interim results for a Phase II study of R115777 (Zarnestra) in patients with relapsed and refractory acute myelogenous leukemia. Proc. Am. Soc. Clin. Oncol. (2002) 21:265a (Abstract 1056).
35. KARP JE, LANCET JE, KAUFMANN SH et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a Phase I clinical-laboratory correlative trial. Blood (2001) 97:3361-3369.
36. CUNNINGHAM D, DE GRAMONT A, SCHEITHAUER W et al.: Randomized double-blind placebo controlled trial of the farnesil transferase inhibitor R115777 (Zarnestra) in advanced refractory colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:126a (Abstract 502).
37. PICCART-GEBHART MJ, BRANLE F, DE VALERIOLA D et al.: A Phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 + docetaxel: a promising combination in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:80a (Abstract 316).
38. VERSLYPE C, VAN STEENBERGEN W, HUMBLET Yet et al.: Phase I trial of 5-FU/LV in combination with the farnesyltransferase inhibitor R115777. Proc. Am. Soc. Clin. Oncol. (2001) 20:171a (Abstract 681).
39. H0LDEN SN, ECKHARDT S, FISHER S et al.: A Phase I pharmacokinetic and biological study of the farnesyl transferase inhibitor R115777 and capecitabine in patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. (2001) 20:80a (Abstract 316).
40. VERWEIJ J, KEHRER D, PLANTING A et al.: Phase I trial of irinotecan in combination with the farnesyl transferase inhibitor R115777. Proc. Am. Soc. Clin. Oncol. (2001) 20:81a (Abstract 319).
41. LIEBES L, HOCHSTER H, SPEYER J et al.: Enhanced myelosuppression of topotecan when combined with the farnesyl transferase inhibitor R115777: a Phase I and pharmacodynamic study. Proc. Am. Soc. Clin. Oncol. (2001) 20:81a (Abstract 321).
42. PATNIK A, ECKHARDT S, ITZBICKA E et al.: A Phase I and pharmacokinetic study of the farnesyl transferase inhibitor R115777 in combination with gemcitabine. Proc. Am. Soc. Clin. Oncol. (2000) 19:2a (Abstract 5A).
43. ADJEI AA, ERLICHMAN C, MARKS RS et al.: A Phase I trial of the farnesyl transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:81a (Abstract 320).
44. SCHWARTZ G, ROWINSKY EK, RHA SY et al: A Phase I, pharmacokinetic and biologic correlative study of R115777 and trastuzumab (Herceptin) in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2001) 20:81a (Abstract 322).
45. VAN CUTSEM E, KARASEK P, OETTLE H et al.: Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:130a (Abstract 517).
46. ROSE WC, LEE FYF, FAIRCHILD CR et al.: Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyl transferase inhibitor. Cancer Res. (2001) 61:7507-7517.
47. RYAN DP, EDER JP, SUPKO JG et al.: Phase I clinical trial of the farnesyl transferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:185a (Abstract 720).
48. CAMACHO LH, SOIGNET SL, PEZZULLI S et al.: Dose escalation study of oral farnesyl transferase inhibitor BMS-214662 in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:79a (Abstract 311).
49. VOI M, TABARNERO J, COOPER MR et al.: A Phase I study of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 1-hour infusion in patients with advanced solis tumors: clinical findings. Proc. Am. Soc. Clin. Oncol. (2001) 20:79a (Abstract 312).
50. TABARNERO J, SONNICHSEN D, ALBANELL J et al.: A Phase I pharmacokinetic and serial tumor and PBMC pharmacodynamic study of weekly BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:77a (Abstract 304).
51. SONNICHSEN D, DAMLE B, MANNING J et al.: Pharmacokinetics and pharmacodynamics of the farnesyl transferase inhibitor BMS-214662 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2000) 19:178a (Abstract 691).
52. ZHU AX, SUPKO JG, RYAN DP et al.: A Phase I clinical pharmacokinetic and pharmacodynamic study of the farnesyltransferase inhibitor BMS-214662 given as a 24-hour continuous intravenous infusion once weekly X 3 in patients with advanced solid rumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:92a (Abstract 366).
53. BAILLEY H, THOMAS J, MARNOCHA R et al.: A Phase I study of weekly BMS-214662, a novel farnesyl protein transferase inhibitor, combined with weekly paclitaxel. Eur. J. Cancer (2002) 38:S55 (Abstract 172).
54. MACKAY HJ, HOEKSTRA R, ESKENS F et al.: A Phase I dose escalating study of BMS-214662 in combination with cisplatin in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. (2001) 20:80a (Abstract 315).
55. DY GK, BRUZEK LM, CROGHAN GA et al.: A Phase I trial of the novel farnesyl protein transferase inhibitor BMS-214662in combination with paclitaxel and carboplatin in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. (2002) 43(Abstract 2736).
56. BRITTEN CD, ROWINSKY EK, SOIGNET S et al.: A Phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies. Clin. Cancer Res. (2001) 7:3894-3903.
57. COHEN-JONATHAN E, EVANS SM, KOCH CJ et al.: The farnesyl transferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res. (2001) 61:2289-2293.
58. GUPTA AK, BAKANAUSKAS VJ, CERNIGLIA GJ et al.: The ras radiation resistance pathway. Cancer Res. (2001) 61:4278-4282.
59. LIU A. CERNIGLIA GJ, BERNHARD EJ et al.: RhoB is required to mediate apoptosis in neoplastically transformed cells after DNA damage. Proc. Natl. Acad. Sci. USA (2001) 98:6192-6197.
60. DORR A, BRUCE J, MONIA B et al.: Phase I and pharmacokinetic trial of ISIS 2503, a 20-Mer antisense oligonucleotide against H-RAS by 14-day continous infusion in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:157a (Abstract 603).
61. HOLMLUND JT, RUDIN CM, MANI S et al.: Phase I trial of ISIS 5132/ODN 698A, a 20-Mer phosphorothioate antisense oligonucleotide inhibitor of C-RAF kinase, administered by a 24-hour weekly intravenous infusion to patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (1999) 18:157a (Abstract 605).
62. AWADA A, HENDLISZ A, GIL T et al.: Final results of a clinical and pharmacokinetic Phase I study of the Ras kinase inhibitor BAY 43-9006 in refractory solid cancers: a promising anti-tumor agent. Eur. J. Cancer (2002) 38:S52 (Abstract 162).
63. HIRTE H, MOORE M, HOTTE S et al.: Final results of a Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumours. Eur. J. Cancer (2002) 38:S55 (Abstract 173).
64. STRUMBERG D, VOLIOTIS D, MOELLER JG et al.: A clinical Phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors. Eur. J. Cancer (2002) 38:S53 (Abstract 167).
65. LORUSSO PM, ADJEI AA, MEYER MB et al.: A Phase I clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:81a (Abstract 321).
66. VAN GOLEN KL, BAO L, DIVITO MM et al.: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther. (2002) 1:575-583.